Education
About Us
Working with TipRanks
Follow Us
Pharvaris (PHVS)
NASDAQ:PHVS
PHVS Stock Chart & Stats
Day’s Range― - ―
52-Week Range$11.51 - $26.33
Previous CloseN/A
Volume14.65K
Average Volume (3M)177.14K
Market Cap
$1.55B
Enterprise Value$728.99M
Total Cash (Recent Filing)$280.73M
Total Debt (Recent Filing)$861.47K
Price to Earnings (P/E)―
Beta0.68
Next Earnings
Nov 05, 2025EPS Estimate
-0.78Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.96
Shares Outstanding64,055,640
10 Day Avg. Volume266,151
30 Day Avg. Volume177,143
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.47
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-5.37K
Enterprise Value/Ebitda-5.01
Forecast
1Y Price Target
$36.17Price Target Upside49.71% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering6
Bulls Say, Bears Say
Bulls Say
Clinical ProgressPharvaris now expects topline data from the pivotal Ph3 RAPIDe-3 trial earlier than the previously anticipated readout, driven by a faster-than-expected accrual of attacks in the study.
Financial StabilityPHVS guided to a cash runway into 1H27, indicating strong financial stability for the company.
Product EfficacyEncouragement is drawn from the update, continuing to see deucrictibant delivering 'injection-like' efficacy across the on-demand and prophylactic treatment.
Bears Say
Competitive PositioningAnalyst maintains an Underperform rating with a $14 price objective, indicating concerns about PHVS's competitive positioning in the HAE market.
Market CompetitionEkterly will have at least 12 months of market exclusivity before PHVS can enter the market, potentially affecting PHVS's market share capture.
Market OpportunityThe opportunity for deucrictibant could be limited to Orladeyo-failures given the 'stickiness' of the market.
Pharvaris News
PHVS FAQ
What was Pharvaris’s price range in the past 12 months?
Pharvaris lowest stock price was $11.51 and its highest was $26.33 in the past 12 months.
What is Pharvaris’s market cap?
Pharvaris’s market cap is $1.55B.
When is Pharvaris’s upcoming earnings report date?
Pharvaris’s upcoming earnings report date is Nov 05, 2025 which is in 37 days.
How were Pharvaris’s earnings last quarter?
Pharvaris released its earnings results on Aug 12, 2025. The company reported -$0.963 earnings per share for the quarter, missing the consensus estimate of -$0.889 by -$0.074.
Is Pharvaris overvalued?
According to Wall Street analysts Pharvaris’s price is currently Undervalued.
Does Pharvaris pay dividends?
Pharvaris does not currently pay dividends.
What is Pharvaris’s EPS estimate?
Pharvaris’s EPS estimate is -0.78.
How many shares outstanding does Pharvaris have?
Pharvaris has 64,055,640 shares outstanding.
What happened to Pharvaris’s price movement after its last earnings report?
Pharvaris reported an EPS of -$0.963 in its last earnings report, missing expectations of -$0.889. Following the earnings report the stock price went up 1.612%.
Which hedge fund is a major shareholder of Pharvaris?
Currently, no hedge funds are holding shares in PHVS
Pharvaris Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$36.17 (49.71% Upside)
$36.17 (49.71% Upside)
Blogger Sentiment
Bullish
PHVS Sentiment 100%
Sector Average 72%
Sector Average 72%
Crowd Wisdom
Very Positive
Last 7 Days ▼ 1.3%
Last 30 Days ▲ 15.1%
Last 30 Days ▲ 15.1%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
27.92%
12-Months-Change
Fundamentals
Return on Equity
-63.96%
Trailing 12-Months
Asset Growth
-34.69%
Trailing 12-Months
Company Description
Pharvaris
Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist that is in Phase II clinical trial for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks and is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients and is under Phase 1 clinical trial. It operates in the Netherlands, Switzerland, and the United States. The company was incorporated in 2015 and is based in Leiden, the Netherlands.
PHVS Stock 12 Month Forecast
Average Price Target
$36.17
▲(49.71% Upside)
Technical Analysis
Ownership Overview
―
Insiders
7.19% Mutual Funds
59.18% Other Institutional Investors
33.02% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---